v3.26.1
Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Series A Non-Voting Convertible Preferred Stock
Series A Non-Voting Convertible Preferred Stock
Preferred Stock
Series B Non-Voting Convertible Preferred Stock
Series B Non-Voting Convertible Preferred Stock
Preferred Stock
Beginning balance, preferred stock (in shares) at Dec. 31, 2024             346,000   17,000
Beginning balance at Dec. 31, 2024 $ 517,804 $ 13 $ 1,334,223 $ 180 $ (972,432)   $ 146,425   $ 9,395
Beginning balance, common stock (in shares) at Dec. 31, 2024   60,257,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)   19,000              
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan 218   218            
Stock-based compensation expense 8,859   8,859            
Foreign currency translation adjustment 14     14          
Unrealized gain on marketable securities 488     488          
Net loss (44,773)       (44,773) $ (8,288)   $ (399)  
Ending balance, preferred stock (in shares) at Mar. 31, 2025             346,000   17,000
Ending balance at Mar. 31, 2025 482,610 $ 13 1,343,300 682 (1,017,205)   $ 146,425   $ 9,395
Ending balance, common stock (in shares) at Mar. 31, 2025   60,276,000              
Beginning balance, preferred stock (in shares) at Dec. 31, 2025           346,045 346,000 16,667 17,000
Beginning balance at Dec. 31, 2025 $ 715,236 $ 15 1,686,167 869 (1,127,635)   $ 146,425   $ 9,395
Beginning balance, common stock (in shares) at Dec. 31, 2025 78,189,811 78,190,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock in connection with at-the-market offering program, net of financing costs (in shares)   296,000              
Issuance of common stock in connection with at-the-market offering program, net of financing costs $ 9,747   9,747            
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)   354,000              
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan 3,663   3,663            
Stock-based compensation expense 12,806   12,806            
Foreign currency translation adjustment 0                
Unrealized gain on marketable securities (1,636)     (1,636)          
Net loss (69,005)       (69,005) $ (10,264)   $ (494)  
Ending balance, preferred stock (in shares) at Mar. 31, 2026           346,045 346,000 16,667 17,000
Ending balance at Mar. 31, 2026 $ 670,811 $ 15 $ 1,712,383 $ (767) $ (1,196,640)   $ 146,425   $ 9,395
Ending balance, common stock (in shares) at Mar. 31, 2026 78,839,858 78,840,000